Amide derivatives of Gallic acid: Design, synthesis and evaluation of inhibitory activities against in vitro α-synuclein aggregation
- Bioorg Med Chem. 2020 Aug 1;28(15):115596. doi: 10.1016/j.bmc.2020.115596.
- 1. College of Chemistry and Institute of Green Catalysis, Zhengzhou University, Daxue Road 75, 450052 Zhengzhou, China.
- 2. College of Chemistry and Institute of Green Catalysis, Zhengzhou University, Daxue Road 75, 450052 Zhengzhou, China. Electronic address: [email protected].
- 3. School of Basic Medical Science, Neuroscience Research Institute, Academy of Medical Sciences, Zhengzhou University, Kexue Road 100, 450001 Zhengzhou, China. Electronic address: [email protected].
- 4. College of Pharmacy, Xinxiang Medical University, Jinsui Road 601, 453003 Xinxiang, China. Electronic address: [email protected].
Gallic acid (GA), a natural phenolic acid, has received numerous attention because of its anti-oxidative, anti-inflammatory, and anti-cancer activity. More importantly, GA can act as an efficient inhibitor of α-synuclein (α-Syn) aggregation at early stages. Nevertheless, some evidences suggest that GA is unlikely to cross the blood-brain barrier because of its high hydrophilicity. Hence, GA may not be considered as a promising candidate or entering brain and directly affecting the central nervous system. Accordingly, we have designed and synthesized a series of amide derivatives of GA, some of which possess appropriate lipophilicity and hydrophilicity with LogP (2.09-2.79). Meanwhile, these sheet-like conjugated compounds have good π-electron delocalization and high ability of hydrogen-bond formation. Some compounds have shown better in vitro anti-aggregation activities than GA towards α-Syn, with IC50 down to 0.98 μM. The valid modification strategy of GA is considered an efficient way to discover novel inhibitors of α-Syn aggregation.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: α-synucleinResearch Areas: Neurological Disease
-
target: α-synucleinResearch Areas: Neurological Disease
-
target: α-synucleinResearch Areas: Neurological Disease
-
target: α-synucleinResearch Areas: Neurological Disease